文献速递头颈外科

循环肿瘤组织修饰病毒HPV DNA与口咽癌疾病负荷的相关性

Circulating Tumor Tissue-Modified-Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-07-07

这项回顾性队列研究纳入94例HPV相关口咽鳞状细胞癌患者,评估治疗前血浆肿瘤组织修饰病毒(TTMV)-HPV DNA水平与影像、检查及手术病理所示疾病范围的相关性。治疗前TTMV-HPV DNA水平与临床淋巴结分期、CT及手术病理所示最大淋巴结径、CT所示转移淋巴结数目、临床结外扩展征象及淋巴结SUV最大值独立相关。

要点

  • 治疗前TTMV-HPV DNA水平与HPV相关OPSCC淋巴结疾病负荷显著相关。
  • 相关性见于治疗前CT、PET及手术病理所评估的淋巴结病变。
  • 研究为单中心回顾性队列,纳入94例治疗前有基线TTMV-HPV DNA检测结果的患者。

核心结论

  • 治疗前TTMV-HPV DNA水平与HPV相关口咽鳞状细胞癌的淋巴结疾病负荷显著相关,评估依据包括治疗前CT、PET及手术病理。

研究设计与样本

  • 回顾性队列研究,单中心三级医疗中心,时间范围2022年1月至2024年7月。
  • 共纳入94例HPV相关口咽鳞状细胞癌患者,均有治疗前基线TTMV-HPV DNA水平。
  • 采用市售TTMV-HPV DNA检测,通过多变量线性回归评估与log(治疗前TTMV-HPV DNA水平)的相关性。

主要发现

  • 患者93%为男性,中位年龄63岁(四分位距[IQR] 55-70)。
  • 临床肿瘤分期以cT1(40%)或cT2(38%)为主,临床淋巴结分期以cN1(77%)为主,37%的患者接受了手术切除。
  • 治疗前TTMV-HPV水平中位数为225(IQR 46-1132)片段/mL。
  • 治疗前TTMV-HPV水平与临床淋巴结分期独立相关(P < .001),与治疗前CT所示最大淋巴结径(r = 0.63 [95%CI: 0.46-1.2];P < .001)及手术病理所示最大淋巴结径(r = 0.63 [0.18-1.08;P = .01])独立相关。
  • 治疗前TTMV-HPV水平与CT所示转移淋巴结数目(r = 0.52 [0.2-0.84];P < .001)、临床结外扩展征象(r = 1.66 [0.12-3.2];P = 0.04)及淋巴结SUV最大值(r = 0.16 [0.05-0.27];P < 0.001)独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tumor-tissue modified viral (TTMV)-human papillomavirus (HPV) DNA is an increasingly utilized biomarker for patients with HPV-mediated oropharyngeal squamous cell carcinoma (OPSCC). However, much remains to be studied regarding the quantitative importance of a positive pre-treatment result and correlations with disease burden. STUDY DESIGN: Retrospective cohort study. SETTING: Single tertiary care center; January 2022 to July 2024. METHODS: Patients with HPV-associated OPSCC and baseline pre-treatment TTMV-HPV DNA levels were evaluated for primary tumor and lymph node disease extent on clinical imaging, exam, and surgical pathology results when applicable. Associations with log(pre-treatment TTMV-HPV DNA levels) were evaluated via multivariable linear regression. A commercially available TTMV-HPV DNA test was used. RESULTS: In total, 94 patients were included, who were 93% male, with median age of 63 years (interquartile range [IQR] 55-70). Most patients were clinical tumor class cT1 (40%) or cT2 (38%) and clinical nodal class cN1 (77%). Surgical resection was performed in 37% of patients. Median pretreatment TTMV-HPV level was 225 (IQR 46-1132) fragments/mL. Independent associations were found between pretreatment TTMV-HPV levels and clinical nodal staging (P < .001), largest lymph node dimension on pretreatment CT (r = 0.63 [95% confidence interval [CI]: 0.46-1.2]; P < .001) and surgical pathology (r = 0.63 [0.18-1.08; P = .01), number of metastatic nodes on CT (r = 0.52 [0.2-0.84]; P < .001), clinical signs of extranodal extension (r = 1.66 [0.12-3.2]; P = 0.04), and SUV-max of lymph nodes (r = 0.16 [0.05-0.27]; P < 0.001). CONCLUSIONS: Pre-treatment TTMV-HPV DNA was significantly associated with lymph node disease burden in HPV-associated OPSCC, on pre-treatment CT, PET, and surgical pathology.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Lee J, McAdoo A, Fassler C, et al. Circulating Tumor Tissue-Modified-Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2025. PMID: 40624873. doi:10.1002/ohn.1345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。